New probe could help surgeons more accurately remove tumours

DUBLIN, 2 July, 2019: A study led by researchers at RCSI’s Department of Chemistry has the potential to help surgeons more accurately remove tumours and detect cancer in lymph nodes during surgery. The research, led by RCSI Professor of Chemistry Donal O’Shea, has been published in Chemical Science.

Bringing together expertise in chemistry and biotechnology, the research team has identified the potential benefit of fluorescence imaging as a way of detecting cancer cells during surgery, developing a probe that lights up when it detects cancer.

According to Professor O’Shea, “This is a very significant development which has the potential to transform the surgical management of cancer, improving outcomes for patients. Almost 60% of all cancer patients will undergo surgery as part of their treatment.”

“A new technology that could improve surgical outcomes by giving the surgical team real-time, informative images during the surgical procedure would have a wide-ranging and sustained impact on the care of cancer patients.”

Addressing the next steps, Professor O’Shea said, “At the moment, this is science. A clinical trial is our next goal and that would allow the full potential of this discovery to be realised for patients, enhancing detection of life-threatening diseases and improving outcomes of surgical procedures.”

The team has recently secured funding for a project on colorectal cancer diagnosis and treatment under the Project Ireland 2040 Disruptive Technology Innovation Fund in collaboration with leading cancer surgeon Professor Ronan Cahill in the Mater University Hospital, UCD and Dublin based industry partners IBM-research and Deciphex.

The project will look at combining tissues responsive probes, artificial intelligence and machine learning to transform medical care for colorectal cancer patients.

###

This paper, RGD Conjugated Cell Uptake Off to On Responsive NIR-AZA Fluorophores: Applications toward Intraoperative Fluorescence Guided Surgery published in the current edition of Chemical Science, is part of a series of research outputs on the clinical potential of fluorescence. Dr Dan Wu, Postdoctoral Fellow in the RCSI Department of Chemistry, is the first author on the paper. Another paper, on PEGylated BF2-Azadipyrromethene (NIR-AZA) fluorophores, for intraoperative imaging, was recently published in the European Journal of Medicinal Chemistry.

RCSI is ranked among the top 250 (top 2%) of universities worldwide in the Times Higher Education World University Rankings (2019) and its research is ranked first in Ireland for citations. It is an international not-for-profit health sciences institution, with its headquarters in Dublin, focused on education and research to drive improvements in human health worldwide. RCSI has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.